Detalhe da pesquisa
1.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844613
2.
Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.
Methods
; 130: 23-35, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743635
3.
Conductivity of mammary gland secretions is a sensitive and specific predictor of parturition in mares.
Equine Vet J
; 56(4): 719-725, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38403880
4.
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Eur J Cancer
; 201: 113588, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38377773
5.
Cancer risk among tetrafluoroethylene synthesis and polymerization workers.
Am J Epidemiol
; 178(3): 350-8, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23828249
6.
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
Cancers (Basel)
; 15(12)2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37370830
7.
The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities.
Cancer Drug Resist
; 6(3): 499-516, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37842243
8.
Whole-Body Composition Features by Computed Tomography in Ovarian Cancer: Pilot Data on Survival Correlations.
Cancers (Basel)
; 15(9)2023 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37174067
9.
Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
Explor Target Antitumor Ther
; 3(2): 149-171, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36046840
10.
Effect of platelet lysate on uterine response of mares susceptible to persistent mating-induced endometritis.
Theriogenology
; 179: 204-210, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34894489
11.
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
Cancers (Basel)
; 14(4)2022 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205700
12.
Luteal Tissue Area and Immunoreactive Concentration of Progesterone in Plasma of Bred and Non-bred Mares.
J Equine Vet Sci
; 118: 104075, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830907
13.
Body composition as a predictor of chemotherapy-related toxicity in ovarian cancer patients: A systematic review.
Front Oncol
; 12: 1057631, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36408182
14.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288469
15.
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.
Cancer Res Commun
; 2(5): 293-306, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36875717
16.
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
Crit Rev Oncol Hematol
; 168: 103539, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34800653
17.
Radiomics in cervical and endometrial cancer.
Br J Radiol
; 94(1125): 20201314, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34233456
18.
Computed Tomography-Based Body Composition in Patients With Ovarian Cancer: Association With Chemotoxicity and Prognosis.
Front Oncol
; 11: 718815, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34868915
19.
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 27(18): 5012-5019, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34266890
20.
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Lung Cancer
; 156: 91-99, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933896